Register for IPO Updates
US IPO Stats
IPO Industry Breakdown
Largest Global IPOs
Largest US IPOs
IPO News Archive
New Ways to Invest in IPOs - IPO ETFs
First two IPOs of 2016 trade up; IPO market continues its 3-year biotech run
Analyst IPO Market Commentary
The IPO market continues its three-year run of biotech offerings.
The Nasdaq Biotech Index is down 23% this year. A whopping 81% of 2015 biotech IPOs trade below issue. Against that backdrop, large biotechs
) delivered solid first-day returns as the first two IPOs of 2016.
Chinese immunotherapy biotech BeiGene priced an upsized IPO at the high end of the range ($158 million) and gained 18%. It was the first biotech IPO to price above the midpoint since September's REGENXBIO (
; -44%). However, the deal was supported by its largest shareholders, who committed to buying up 50% of the offering.
Preclinical gene editing biotech Editas Medicine priced at the low end ($94 million) and nearly broke its offer price, but finished its debut up 14%. Founded in 2013, the Editas IPO demonstrated investor demand for very early-stage biotechs, and provided an enviably quick turnaround for its backers, both venture (Flagship, Polaris, Third Rock) and crossover (Fidelity, T. Rowe, Jennison, Google). No insiders publicly indicated on the deal.
Biotech IPO activity exploded alongside massive biotech returns during the past three years.
One in three IPOs was a biotech in 2015.
More biotechs on
the IPO calendar
Early-stage gene therapy biotech
), underwritten by Goldman, is hoping to raise $85 million next week. Backed by Deerfield, Venrock and T. Rowe, insiders have indicated on 35% of the float. Cystic fibrosis biotech
) plans to raise $50 million; insiders have indicated on 60% of the deal - more than 97% of 2015 biotechs.
Even more biotechs in the IPO pipeline
The biotech sector could power the IPO market through the rest of the quarter as well. Of the 17 new IPO filings in January, there were 13 health care companies, including 11 biotechs. Two biotechs are looking to raise $115 million: Corvus Pharmaceuticals (
) and Oncobiologics (
Still no tech IPOs:
High-growth names like
) filed publicly in December, but volatility, the broad sell-off, and particularly poor performance from peers have likely caused them to delay setting terms.
Keywords / Tickers:
Recently Priced IPOs
ETF Express Award:
ETFExpress awards are based on a 'peer review system' whereby readers - including institutional and high net worth investors as well as managers and other industry professionals at fund administrators, brokers, custodians and advisers - are invited to elect a 'best in class' in a series of categories via an online survey. In each category, the firms with the most votes at the end of the voting period are subject to a final review by ETFExpress's Senior Editorial team.
Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.
As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund's average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees.
An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.
Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds.
Renaissance IPO Index® (IPOUSA)
is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios.
Renaissance International IPO Index® (IPOXUS)
is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges.
The S&P 500® Index (SPX) is a stock market index which includes 500 U.S. listed companies and seeks to capture approximately 80% coverage of available U.S. market capitalization.
Risk Disclosure: Investments in the
Renaissance IPO ETF, symbol "IPO"
Renaissance International IPO ETF, symbol "IPOS"
(the "ETFs"), and the
Global IPO Fund, symbol "IPOSX"
(the "Mutual Fund") are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the "Funds") invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.
Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit
. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Definitions: The Renaissance IPO Index® is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The S&P 500® Index is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE or Nasdaq.
The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.
Register for Updates
Renaissance Capital LLC is an SEC-registered investment adviser.
Renaissance Capital Investments, Inc. is a
-registered broker-dealer, and member of
© 2016 Renaissance Capital LLC. All rights reserved.